Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. / Fang, Evandro F; Hou, Yujun; Palikaras, Konstantinos; Adriaanse, Bryan A; Kerr, Jesse S; Yang, Beimeng; Lautrup, Sofie; Hasan-Olive, Md Mahdi; Caponio, Domenica; Dan, Xiuli; Rocktäschel, Paula; Croteau, Deborah L; Akbari, Mansour; Greig, Nigel H; Fladby, Tormod; Nilsen, Hilde; Cader, M Zameel; Mattson, Mark P; Tavernarakis, Nektarios; Bohr, Vilhelm A.
In: Nature Neuroscience, Vol. 22, 2019, p. 401-412.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease
AU - Fang, Evandro F
AU - Hou, Yujun
AU - Palikaras, Konstantinos
AU - Adriaanse, Bryan A
AU - Kerr, Jesse S
AU - Yang, Beimeng
AU - Lautrup, Sofie
AU - Hasan-Olive, Md Mahdi
AU - Caponio, Domenica
AU - Dan, Xiuli
AU - Rocktäschel, Paula
AU - Croteau, Deborah L
AU - Akbari, Mansour
AU - Greig, Nigel H
AU - Fladby, Tormod
AU - Nilsen, Hilde
AU - Cader, M Zameel
AU - Mattson, Mark P
AU - Tavernarakis, Nektarios
AU - Bohr, Vilhelm A
PY - 2019
Y1 - 2019
N2 - Accumulation of damaged mitochondria is a hallmark of aging and age-related neurodegeneration, including Alzheimer's disease (AD). The molecular mechanisms of impaired mitochondrial homeostasis in AD are being investigated. Here we provide evidence that mitophagy is impaired in the hippocampus of AD patients, in induced pluripotent stem cell-derived human AD neurons, and in animal AD models. In both amyloid-β (Aβ) and tau Caenorhabditis elegans models of AD, mitophagy stimulation (through NAD+ supplementation, urolithin A, and actinonin) reverses memory impairment through PINK-1 (PTEN-induced kinase-1)-, PDR-1 (Parkinson's disease-related-1; parkin)-, or DCT-1 (DAF-16/FOXO-controlled germline-tumor affecting-1)-dependent pathways. Mitophagy diminishes insoluble Aβ1-42 and Aβ1-40 and prevents cognitive impairment in an APP/PS1 mouse model through microglial phagocytosis of extracellular Aβ plaques and suppression of neuroinflammation. Mitophagy enhancement abolishes AD-related tau hyperphosphorylation in human neuronal cells and reverses memory impairment in transgenic tau nematodes and mice. Our findings suggest that impaired removal of defective mitochondria is a pivotal event in AD pathogenesis and that mitophagy represents a potential therapeutic intervention.
AB - Accumulation of damaged mitochondria is a hallmark of aging and age-related neurodegeneration, including Alzheimer's disease (AD). The molecular mechanisms of impaired mitochondrial homeostasis in AD are being investigated. Here we provide evidence that mitophagy is impaired in the hippocampus of AD patients, in induced pluripotent stem cell-derived human AD neurons, and in animal AD models. In both amyloid-β (Aβ) and tau Caenorhabditis elegans models of AD, mitophagy stimulation (through NAD+ supplementation, urolithin A, and actinonin) reverses memory impairment through PINK-1 (PTEN-induced kinase-1)-, PDR-1 (Parkinson's disease-related-1; parkin)-, or DCT-1 (DAF-16/FOXO-controlled germline-tumor affecting-1)-dependent pathways. Mitophagy diminishes insoluble Aβ1-42 and Aβ1-40 and prevents cognitive impairment in an APP/PS1 mouse model through microglial phagocytosis of extracellular Aβ plaques and suppression of neuroinflammation. Mitophagy enhancement abolishes AD-related tau hyperphosphorylation in human neuronal cells and reverses memory impairment in transgenic tau nematodes and mice. Our findings suggest that impaired removal of defective mitochondria is a pivotal event in AD pathogenesis and that mitophagy represents a potential therapeutic intervention.
U2 - 10.1038/s41593-018-0332-9
DO - 10.1038/s41593-018-0332-9
M3 - Journal article
C2 - 30742114
VL - 22
SP - 401
EP - 412
JO - Nature Neuroscience
JF - Nature Neuroscience
SN - 1097-6256
ER -
ID: 213361371